JAPAN’S PHARMACEUTICAL AND BIOTECH DRUG DEVELOPMENT PROGRAMS GAIN EASY ACCESS AND TECHNICAL SUPPORT OF CROWNBIO’S UNIQUE TRANSLATIONAL ONCOLOGY ASSETS HUPRIME® AND HUBASE™ WITH JAPAN’S PREMIER TECHNICAL SALES ORGANIZATION ON TARGET.
Santa Clara, California (PRWEB) August 11, 2011
Crown Bioscience (CrownBio), a leading biotech company specializing in oncology and diabetes research announces today that it has signed an agreement with Japan-based On Target Co., Ltd. (On Target) appointing On Target as its official representative in Japan. This agreement permits On Target to promote, market, and broker CrownBio’s preclinical drug discovery services throughout Japan. Crown Bioscience Vice President of Business Development Laura Sailor comments that, “Our agreement with On Target will greatly increase the visibility of CrownBio’s unique and comprehensive range of oncology and diabetes services to Japan’s research community while making it more convenient than ever to integrate CrownBio’s expertise into their development programs. CrownBio has developed an excellent working relationship with On Target and has every confidence in On Target’s ability to provide our clients in Japan with the high level of customer service and support for which we are known.” “On Target is both extremely pleased and proud to represent Crown Bioscience in Japan,” says On Target Sales Director, Keiichi Yokohama, PhD. “CrownBio is clearly an established leader among drug discovery solution providers. CrownBio’s comprehensive, state-of-the-art services in oncology and diabetes offer clients exciting new options to focus and accelerate their drug development efforts. On Target truly looks forward to helping Japan’s researchers take full advantage of CrownBio’s expertise.
About Crown Bioscience Inc.
Crown Bioscience, Inc. is a leading biotech company that provides its global biopharmaceutical industry partners with innovative and integrated solutions. Leveraging on its proprietary technology platforms in structure-based drug design and translational oncology, the company pioneers a business model that addresses the critical need of the pharmaceutical industry to improve R&D productivity while minimizing risks and retaining upside. Since its inception, CrownBio has been providing value-added services to help partners to identify the most promising compounds for clinical testing, and more importantly, enable its partners to develop strategies for biomarker development and patient stratification, an effort central to developing personalized cancer therapeutics.
As a leading cancer drug discovery partner, the company has established strategic partnerships with Pfizer and other large global pharmaceutical companies and leading Chinese pharmaceutical firms. The mandate of these partnerships is to deliver oncology clinical candidates with well defined clinical development path. By deploying its full capabilities across key functional disciplines in target validation, protein engineering, fragment-based drug design, medicinal/computational chemistry, formulation, DMPK, quantitative biology, pharmacology, and biomarker discovery, the company functions as a highly efficient external drug discovery engine to complement its partners’ internal drug R&D effort. It is actively working with other biotech and pharmaceutical companies to establish similar partnerships in oncology and other disease areas.
For more information please visit our web site at www.crownbio.com
Laura Sailor – email@example.com +1 606 686 9330
About On Target, Co. Ltd.
On Target’s singular mission is to accelerate pre-clinical drug discovery and development by providing the Japan pharma and biotech community with rapid and seamless access to high value services and products from carefully selected international partners. With years of prior experience, On Target prides itself on its ability to support Japan’s pharma and biotech researchers with detailed product knowledge, service logistics, and round-the-clock attention to the needs of its customers.
For more information, please visit our web site at http://www.ontarget-ddss.co.jp
On Target Co., Ltd. Keiichi Yokoyama, PhD